Diagnostic relevance of circulating biomarkers in patients with lung cancer
Diagnostic relevance of circulating biomarkers in patients with lung cancer
复制标题
DOI：
10.3233/cbm-2009-0127
复制
发表时间：
2010-01-01
影响因子：
3.1
通讯作者：
Stieber, Petra
中科院分区：
文献类型：
--
作者：
Molina, Rafael;Holdenrieder, Stefan;Stieber, Petra
对可疑肺部肿块的鉴别诊断对于选择合适的治疗策略是至关重要的。虽然早期非小细胞肺癌(NSCLC)和其他癌症的单肺转移大多通过手术切除，但晚期非小细胞肺癌(NSCLC)、小细胞肺癌(SCLC)和多发性肺转移瘤则采用全身化疗和/或放射治疗。在许多患者中，由于患者的多发病和临床条件不稳定或肿瘤部位不利，无法进行组织病理亚型的活检。此外，肺部肿瘤的异质性可能意味着在一个可疑病变中存在不同类型的恶性细胞。由于血液中的肿瘤相关生物标记物反映了癌细胞的生化特性，它们的释放或不释放可能有助于支持临床决策。本文综述了基于血清的生物标记物在肺癌鉴别诊断中的潜力和作用，并反映在美国国家临床生物化学研究院(NACB)的新建议中。
Differential diagnosis of suspicious lung masses is essential for the selection of the appropriate therapy strategy. While non-small cell lung cancer (NSCLC) in early stages and single lung metastases from other cancers mostly are resected by surgery, late stage NSCLC, small cell lung cancers (SCLC) and multiple lung metastases are treated by systemic chemo- and/or radiotherapeutic approaches.In many patients, biopsies for the histopathological subtyping can not be taken due to multimorbidity and instable clinical conditions of the patient or unfavourable localisation of the tumor. In addition, heterogeneity of lung tumors may imply the presence of different malignant cell types in one suspicious lesion. As tumor-related biomarkers in blood reflect the biochemical properties of cancer cells, their release or non-release may be helpful to support the clinical decision making.This review summarizes the current knowledge about the potential and the role of serum-based biomarkers for the differential diagnosis of lung cancer which is also mirrored in the new recommendations of the National Academy of Clinical Biochemistry (NACB).